ClinicalTrials.Veeva

Menu

Histological Differentiation Grade Predicted by Ultrasound Backscatterer Imaging

National Taiwan University logo

National Taiwan University

Status

Unknown

Conditions

Neoplastic Disease
Pathology

Study type

Observational

Funder types

Other

Identifiers

NCT02786199
201505107RINA

Details and patient eligibility

About

Histological grade of hepatocellular carcinoma (HCC) is an important prognostic factor affecting patient survival. It has been divided into four grades from I to IV on the basis of histological differentiation. Grade I is the best differentiated consisting of small tumor cells arranged in thin trabeculae. Cells with higher grade are larger and less differentiated with hyperchromatic nuclei and loss of trabecular pattern.

Ultrasound is an imaging modality frequently used to evaluate liver tumors because of its convenience, real-time, less expensive and no radiation exposure. However, ultrasonographic evaluation by conventional B-mode image is semi quantitative and subjective. It still cannot replace liver biopsy for the evaluation of HCC.

This study is aimed to quantify the image characters of B-mode image and the scatterer properties using Nakagami distribution. Nakagami parameter is a general model to describe the distribution of scatterers. Therefore, the investigators hypothesized that Nakagami parameter may also reflect the histological changes in different grades of HCC.

In this study, the resected HCC tumor samples will be collected from the participants who are going to receive surgical resection, and the tumor US images and Nakagami values will be obtained via the single-element ultrasound system. The correlation between the ultrasound backscatter parameter and the differentiation grade will be analyzed.

Enrollment

100 estimated patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 21 to 75
  • Patients with HCC who underwent surgery
  • The resected tumor was measured larger than 3 cm

Exclusion criteria

  • Patients who have received other treatment in 6 months
  • Patients who couldn't regular follow-up

Trial design

100 participants in 1 patient group

Hepatocellular carcinoma
Description:
patients HCC who are going to receive surgical resection

Trial contacts and locations

1

Loading...

Central trial contact

Ming-Chih Ho, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems